Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viekirax + Ribavirin in Japanese Genotype 2 HCV
NCT02023112Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of paritaprevir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Jan 2014; status: completed.
02
Drugs
paritaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02023112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023112.